Previous close | 1,250.80 |
Open | 1,260.15 |
Bid | 1,249.04 x 800 |
Ask | 1,260.83 x 800 |
Day's range | 1,240.45 - 1,266.91 |
52-week range | 928.50 - 1,411.61 |
Volume | |
Avg. volume | 128,337 |
Market cap | 26.531B |
Beta (5Y monthly) | 1.15 |
PE ratio (TTM) | 34.55 |
EPS (TTM) | 35.90 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1,221.89 |
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Mettler-Toledo's (MTD) first-quarter performance is likely to reflect the adverse impacts of macroeconomic headwinds, and weak momentum across the Industrial and Laboratory segments.
Beyond analysts' top -and-bottom-line estimates for Mettler-Toledo (MTD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.